TMCnet News
TheSUBWAY.com Inc.: Stock Developments for Tuesday, September 16, 2008: PSTI Promising Results!(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:16092008 TheSUBWAY.com: Names the following stocks to its Stock Alerts List: Pluristem Therapeutics Inc. (Nasdaq: PSTI), United Airlines (Nasdaq: UAUA), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Broadcom Corporation (Nasdaq: BRCM), Altera Corporation (NASDAQ:ALTR), Amgen (NASDAQ:AMGN). Visit TheSUBWAY's Small Cap Investor Forum Here: http://investor-forum.thesubway.com/ Pluristem Therapeutics Inc. (Nasdaq: PSTI), announced today the successful conclusion of its pre-clinical efficacy studies utilizing PLX-PAD prior to the initiation of human clinical trials. PLX-PAD is Pluristem's cellular product for the treatment of critical limb ischemia (CLI), the end stage of Peripheral Artery Disease (PAD). Zami Aberman, Pluristem's President and CEO commented, "These final PLX-PAD efficacy studies show impressive new vessel formation and may bring hope to millions of people suffering from complications of diabetes, Buerger's Disease and smoking where insufficient blood flow to their lower legs places them at risk of amputation. The successful completion of the PLX-PAD pre-clinical efficacy trials, in accordance with the regulatory authority's requirements, validates the results we obtained in our previous studies with this product and gives us assurances that allogeneic adherent stromal cells will be efficacious for this disorder. This was our final pre-clinical efficacy study using PLX-PAD and we now intend to commence human trials, following receipt of the necessary regulatory approvals." Technical analysts believe a narrowing of the Bollinger Bands around a Company's stock price suggests a significant movement will soon occur. With PSTI, the bands could not be any narrower. The last two times they approached this level, the stock saw an upswing of over 216% and 60% in share price. Other stocks highlighted include: United Airlines (Nasdaq: UAUA), up 9% on 23 million shares, Monday said that in a challenging economic environment where fuel prices continue to be volatile and are more than 50 percent higher than last year, United is increasing the service fee to check a second bag on a domestic flight from $25 to $50 one way. These changes apply to customers who purchase a ticket on or after Sept. 16, 2008, for travel within the U.S. and to/from Canada, Puerto Rico and the U.S. Virgin Islands on or after Nov. 10, 2008. Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), down 2% on 10 million shares, Monday announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be presented on COPAXONE (glatiramer acetate injection), a leading therapy for relapsing-remitting multiple sclerosis (RRMS) treatment, covering early treatment with COPAXONE , long-term efficacy and safety. Broadcom Corporation (Nasdaq: BRCM), down 3% on 13 million shares, a global leader in semiconductors for wired and wireless communications, Monday announced its next generation of digital television (DTV) system-on-a chip (SoC) solutions that bring advanced functionality and differentiated features to DTV designs to address the U.S. market. Featuring expandable entry-level to high-end design capabilities, the new SoC solutions enable TV manufacturers to enhance the DTV from a commodity display device to a highly differentiated, connected entertainment system. Included in each of these single-chip solutions are an advanced multi-format decoder, Ethernet network connectivity, a 3D graphical user interface, and unique 3D color management, all of which continue to position the TV as the central entertainment appliance for the digital home. Altera Corporation (NASDAQ:ALTR), down 3% on 8 million shares, Monday announced the availability of a 10-gigabit Ethernet (10GbE) reference design targeting designers using the XAUI communications protocol. Line cards and system controllers used within network routers, enterprise and metro Ethernet switches, and storage switches can leverage Altera's Arria and Stratix series of FPGAs to connect reliably to 10GbE backplanes or networks. Altera's 10GbE solution is IEEE 802.3ae standard compliant and successfully passed the University of New Hampshire Interoperability Lab (UNH-IOL) 10GbE tests. Amgen (NASDAQ:AMGN), down 1% on 14 million shares, and Biovitrum AB announced Monday that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance (palifermin) and Stemgen (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value. Kineret, Kepivance and Stemgen generated combined sales of nearly $70 million in 2007. ABOUT TheSUBWAY.com: TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com TheSubway.com is consistently ranked in the top 4 on the StockPromoters.com "Best performing promoters of all time" list. This is out of over 1,000 promoters and promotional campaigns tracked by StockPromoters.com. Visit http://www.StockPromoters.com for more details. All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRGP has been compensated forty thousand shares for PSTI. CRGP intends to sell its shares. CRGP and its web site are operated under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. CONTACT: Joe Farrar, President, CRG Partners, Inc Tel: +1 973 332 1366 WWW: http://www.TheSUBWAY.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2008 M2 Communications Ltd. |
